Artificial Intelligence and Breast Cancer Management: From Data to the Clinic by Kaixiang Feng, Zongbi Yi, Binghe Xu

Get full text

Development of a prognostic model based on the ceRNA network in Triple-Negative Breast cancer by Yimin Zhu, Jiayu Wang, Binghe Xu

Get full text

Immunotherapy in breast cancer: current landscape and emerging trends by Ran Ran, Xi Chen, Jin Yang, Binghe Xu

Get full text

Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer by Wenjie Zhu, Mei Liu, Ying Fan, Fei Ma, Ningzhi Xu, Binghe Xu

Get full text

Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated HR+ and HER2− mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials by Oleg Gluz, Binghe Xu, Rita Nanda, Anandaroop Dasgupta, Ankita Kaushik, Wendy Verret, Akanksha Sharma, Barinder Singh, Hope S. Rugo

Get full text

The characteristics of HER2-positive microinvasive breast cancer and the necessity of systemic adjuvant therapy in these patients: a multicenter real-world study by Bo Lan, Dan Lv, Changyuan Guo, Zitong Feng, Ying Fan, Tao Sun, Jiayi Huang, Xiaoying Sun, Fei Ma, Binghe Xu

Get full text

Stromal PLAU mediates tumor progression and informs a novel therapeutic target in triple-negative breast cancer by Jun Zou, Jingyao Zhang, Yu Li, Baowen Yuan, Yuanyi Wang, Yalong Qi, Qian Wang, Wan Qin, Xianglin Yuan, Binghe Xu

Get full text

Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node‐Positive Breast Cancer... by Danyang Ji, Bo Lan, Jiayu Wang, Fei Ma, Yang Luo, Qing Li, Pin Zhang, Ruigang Cai, Qiao Li, Shanshan Chen, Binghe Xu, Ying Fan

Get full text

The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study by Xuenan Peng, Bo Lan, Jiayu Wang, Qiao Li, Jiani Wang, Ying Fan, Yang Luo, Shanshan Chen, Hongnan Mo, Lixi Li, Xiaoying Sun, Jintao Zhang, Ruigang Cai, Pin Zhang, Binghe Xu, Fei Ma

Get full text

Real-world effectiveness of goserelin 10.8-mg compared to goserelin 3.6-mg in premenopausal and perimenopausal Chinese patients with hormone receptor positive breast cancer: a coho... by Yongsheng Wang, Xi Wang, Jiong Wu, Hong Liu, Jiuda Zhao, Jian Huang, Jianxia Liu, Youling Gong, Hao Wang, Huaqing Yang, Guorong Zou, Quchang Ouyang, Guoqin Jiang, Huijuan Liu, Sujie Ni, Binghe Xu, Jinming Yu

Get full text

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 tri... by Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu

Get full text

Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomize... by Binghe Xu, Qingyuan Zhang, Yang Luo, Zhongsheng Tong, Tao Sun, Changping Shan, Xinlan Liu, Yumin Yao, Bing Zhao, Shusen Wang, Xiaohua Zeng, Changlu Hu, Xi Yan, Xiaojia Wang, Hongyan Jia, Zhendong Chen, Fuming Qiu, Xinhong Wu, Deyong Zhang, Tong Li

Get full text

Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis by Jiayu Wang, Qingyuan Zhang, Huiping Li, Zhongsheng Tong, Quchang Ouyang, Huihui Li, Yuee Teng, Biyun Wang, Tao Sun, Jingfen Wang, Wei Li, Zhaofeng Niu, Hongsheng Li, Chang Gong, Shu Wang, Xinshuai Wang, Xinhong Wu, Ning Liu, Guohua Yu, Fei Liu, Xianghui Duan, Shuya Wang, Yaping Meng, Li Wang, Binghe Xu

Get full text